References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2017-4-4-11

mrj-789

Research Article

ЛЕКЦИИ

LECTURES

Особенности системной красной волчанки с дебютом в пожилом возрасте

Late-onset systemic lupus erythematosus in the elderly

Клюквина

Н. Г.

Klyukvina

N. G.

nataklykvina@yandex.ru

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian Federation

2017

06012018

114411

2018

Клюквина Н.Г.

Klyukvina N.G.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/789

Системная красная волчанка (СКВ) – хроническое аутоиммунное заболевание с вовлечением в патологический процесс различных органов и систем. Существуют убедительные доказательства того, что возраст начала болезни может оказывать влияние на клиническую картину и прогноз СКВ. Проанализированы клинико-лабораторные особенности СКВ с дебютом после 50 лет, возможные причины различий в проявлениях СКВ в зависимости от расовых и генетических факторов. Рассмотрены вопросы дифференциальной диагностики. Представлены данные литературы и результаты собственных исследований.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with various organs and systems involved in the pathological process. There is strong evidence that age at disease onset may influence the clinical presentations and prognosis of SLE. The paper analyzes the clinical and laboratory features of onset of SLE after the age of 50 years and possible reasons for differences in the manifestations of the disease in relation to racial and genetic factors. It considers the problems of differential diagnosis. There are data available in the literature and the results of the author's own investigations.

системная красная волчанка с дебютом в пожилом возрастесистемная красная волчанка у пожилыхпоздний дебют системной красной волчанки

late-onset systemic lupus erythematosus in the elderlysystemic lupus erythematosus in the elderlylate-onset systemic lupus erythematosus

References1

Stefanidou S, Gerodimos C, Benos A, et al. Clinical expression and course in patients with late onset systemic lupus erythematosus. Hippokratia. 2013 Apr;17(2):153-6.

Boddaert J, Huong DLT, Amoura Z, et al. Late-onset systemic lupus erythematosus/ A personal series of 47 patients and pooled analysis of 714 cases in literature. Medicine (Baltimore). 2004 Nov;83(6):348-59.

Padovan M, Govoni M, Castellino G, et al. Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. Rheumatol Int. 2007 Jun;27(8):735-41. Epub 2006 Dec 29.

Cooper GS, Treadwell EL, St Clair EW, et al. Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus. Arthritis Rheum. 2007 Aug 15;57(6):993-9.

Font J, Pallares L, Cervera R, et al. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis. 1991 Oct;50(10):702-5.

Maddock RK. Incidence of systemic lupus erythematosus by age and

sex. JAMA. 1965 Jan 11;191:137-8.

Lalani S, Pope J, de Leon F, Peschken C; Members of CaNIOS/1000 Faces of Lupus. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol. 2010 Jan;37(1):38-44. doi:10.3899/jrheum.080957. Epub 2009 Dec 15.

Alarcon GS, Calvo-Alen J, McGwin G Jr, et al; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis. 2006 Sep;65(9):1168-74.

Maddison P, Farewell V, Isenberg D, et al. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol. 2002 May;29(5):913-7.

Mak SK, Lam EK, Wong AK. Clinical profile of patients with late onset SLE: not a benign subgroup. Lupus. 1998;7(1):23-8.

Domenech I, Aydintug O, Cervera R, et al. Systemic lupus erythematosus in 50 year olds. Postgrad Med J. 1992 Jun;68(800):440-4.

Shaikh SK, Wang F. Late-onset systemic lupus erythematosus: clinical and immunological characteristics. Med J Malaysia. 1995 Mar;50(1):25-31.

Wilson HA, Hamilton ME, Spyker DA. Age influences the clinical and serologic expression of SLE. Arthritis Rheum. 1981 Oct;24(10):1230-5.

Medin JL, Hansen KE, Fitz SR, Bartels CM. A systematic review and meta-analysis of cutaneous manifestations in late versus early-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2016 Jun;45(6): 691-7. doi: 10.1016/j.semarthrit.2016.01.004. Epub 2016 Jan 21.

Manoussis MN, Georgopoulou C, Zintzaras E, et al. Sjogren's syndrome associated with systemic lupus erythematosus. Clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum. 2004 Mar;50(3):882-91.

Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002 Jul; 20(3):373-85, v.

Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002 May;61(5):409-13.

Pu SJ, Luo SF, Wu YJ, et al. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus. 2000;9(2): 96-100.

Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993 Mar;72(2):113-24.

Wilson HA, Hamilton ME, Spyker DA, et al. Age influences the clinical and serologic expression of systemic lupus erythematosus. Arthritis Rheum. 1981 Oct;24(10):1230-5.

Ho CT, Mok CC, Lau CS, Wong RW. Late onset systemic lupus erythematosus in southern Chinese. Ann Rheum Dis. 1998 Jul;57(7):437-40.

Bertoli AM, Alarcon GS, Calvo-Alen J, et al; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum. 2006 May;54(5):1580-7.

Клюквина НГ. Трудности диагностики и особенности клинической картины системной красной волчанки у мужчин. Терапевтический архив. 2011;(5):47-51. [Klyukvina NG. Diagnostic difficulties and clinical features of systemic lupus erythematosus in men. Terapevticheskii arkhiv. 2011;(5):47-51. (In Russ.)].

Клюквина НГ, Насонов ЕЛ. Выживаемость мужчин, страдающих системной красной волчанкой. Научно-практическая ревматология. 2009;47(6): 46-51. [Klyukvina NG, Nasonov EL. Survival of men with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009; 47(6):46-51. (In Russ.)]. doi: 10.14412/ 1995-4484-2009-674

Cervera R, Khamashta MA, Font J,

et al; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 Sep; 82(5):299-308.

Lin H, Wei JC, Tan C, et al. Survival analysis of late-onset systemic lupus erythematosus: a cohort study in China. Clin Rheumatol. 2012 Dec;31(12):1683-9. doi: 10.1007/s10067-012-2073-6. Epub 2012 Sep 15.

Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis. 2002 Dec;61(12):1065-70.

Tomic-Lucic A. Late-onset systemic lupus erythematosus: clinical features, course and prognosis. Clin Rheumatol. 2013 Jul; 32(7):1053-8. doi: 10.1007/s10067-013-2238-y. Epub 2013 Mar 21.

Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum. 1989 Oct;32(10):1226-32.

Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term follow-up of an inception cohort. Arthritis Rheum. 1995 Oct;38(10):1492-9.

Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Feb;42(2):338-46.

Zamber RW, Starkebaum G, Rubin RL, et al. Drug induced systemic lupus erythematosus due to ophthalmic timolol. J Rheumatol. 1992 Jun;19(6):977-9.

Hochberg MC. Mortality from systemic lupus erythematosus in England and Wales, 1974-1983. Br J Rheumatol. 1987 Dec;26(6): 437-41.

Pu SJ, Luo SF, Wu YJ, et al. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus. 2000;9(2): 96-100.

Goobie GC, Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies in systemic lupus erythematosus. Curr Opin Rheumatol. 2015 Sep;27(5):454-60.

doi: 10.1097/BOR.0000000000000202.

Draborg AH, Duus K, Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol. 2012;2012: 370516. doi: 10.1155/2012/370516. Epub 2012 Jul 3.

Rai R, Chauhan SK, Singh VV, et al. Heat shock protein 27 and its regulatory molecules express differentially in SLE patients with distinct autoantibody profiles. Immunol Lett. 2015 Mar;164(1):25-32. doi: 10.1016/j. imlet.2015.01.007. Epub 2015 Feb 2.

Grzegrzolka J, Kurnol K, Piotrow P, et al. Hsp27 expression in invasive ductal breast carcinoma. Folia Histochem Cytobiol. 2012;50(4):527-33. doi: 10.5603/16717.

Lazaro D. Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. Drugs Aging. 2007;24(9):701-15.

Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis. 2006 Nov;65(11): 1500-5. Epub 2006 Apr 20.

Alarcon GS, Calvo-Alen J, McGwin G, et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis. 2006 Sep;65(9):1168-74.

Ballou SP, Khan MA, Kushner I. Clinical features of SLE: differences related to race and age of onset. Arthritis Rheum. 1982 Jan; 25(1):55-60.

Alonso MD, Llorca J, Martinez-Vazquez F, et al. Systemic lupus erythematosus in Notrhwestern Spain. Medicine (Baltimore). 2011 Sep;90(5):350-8. doi: 10.1097/MD. 0b013e31822edf7f.

Hochberg MC, Florsheim F, Scott J, et al. Familial aggregation of systemic lupus erythematosus. Am J Epidemiol. 1985;122:526-31.

Lawrence JS, Martins L, Drake G. A family survey of lupus erythematosus: I. Heritability. J Rheumatol. 1987 Oct;14(5): 913-21.

Graham RR, Ortmann W, Rodine P, et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoanti-bodies in human SLE. Eur J Hum Genet. 2007 Aug;15(8):823-30. Epub 2007 Apr 4.

Criswell LA. The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis. 2008;66(3):176-83.

Wong M, Tsao BP. Current topics in human SLE genetics. Springer Semin Immunopathol. 2006 Oct;28(2):97-107. Epub 2006 Aug 29.

Pan CF, Wu CJ, Chen HH, et al. Molecular analysis of HLADRB1 allelic associations with systemic lupus erythematous and lupus nephritis in Taiwan. Lupus. 2009 Jul;18(8):698-704. doi: 10.1177/ 0961203308101955.

Penaranda-Parada E, Quintana G, Yunis JJ, et al. Clinical, serologic and immunogenetic characterization (HLA-DRB1) of late-onset lupus erythematosus in a Colombian population. Lupus. 2015 Oct; 24(12):1293-9. doi: 10.1177/096120331 5588576. Epub 2015 May 28.

Mok CC, Lau CS, Wong RW. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum. 2001 Jun; 30(6):426-35.

Catania A, Mangone I, Motta P, Zanussi C. Administration of gonadotropin – releasing hormone analog as adjunctive therapy in women with systemic lupus erythematosus. Arthritis Rheum. 1989 Sep;32(9):1186-8.

Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Nov;46(11):2924-7.

Van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus. 1999;8(3):181-7.

Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum. 1999 Jun;42(6): 1274-80.

Steinberg AD, Melez KA, Raveche ES, et al. Approach to the study of the role of sex hormones in autoimmunity. Arthritis Rheum. 1979 Nov;22(11):1170-6.

Sanchez-Guerrero J, Liang HM, Karlson EW, et al. Postmenopausal estrogen therapy and the risk of developing systemic lupus erythematosus. Ann Intern Med. 1995 Mar 15;122(6):430-3.

Mok CC, Lau CS, Lee KW, Wong RW. Hyperprolactinemia in males with systemic lupus erythematosus. J Rheumatol. 1998 Dec; 25(12):2357-63.

Turi MC, D'Urbano M, Celletti E, et al. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age. Arch Gerontol Geriatr. 2009;49 Suppl 1:221-6. doi: 10.1016/j.archger.2009.09.032.

Calvo-Alen J, Toloza SM, Fernandez M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum. 2005 Jul;52(7):2060-8.

The authors declare that there are no conflicts of interest present.